アイルランド - 英語 - HPRA (Health Products Regulatory Authority)

chugai pharma uk ltd - lenograstim - pdr+solv for soln for inf/inj - 34 million iu/ml

オーストラリア - 英語 - APVMA (Australian Pesticides and Veterinary Medicines Authority)

sabakem pty ltd - ethephon (as anti-cholinesterase compound) - soluble concentrate - ethephon (as anti-cholinesterase compound) organophosphorus active 720.0 g/l - growth regulator - apple | apple - legana | apple - stark crimson | cherry - florence | cherry - napoleon | cherry - ron's seedling | cherry - st m - accelerate ripening | acceleration of boll opening | advance/concentrate fruit maturity | aid complete removal of fruit from trees | aid mechanical harvesting | defoliation of cotton plants | early colour development | encourage biennial bearing habit | even out production cycle | fruit thinning | increase fruit maturity or colour | increase fruit yield | initiate flowering in ratoon | initiating flowering | loosen fruit | pre-conditioning treatment | promote eveness of maturity | promote uniform nutfall | reduce size of heavy crop | reduce vegetative growth | stimulate flowering in following season | control excess vine growth | control excess.veg.growth | defoliation aid | fruit thinning | increased red colour | increasing fruit yield | promotes flowering | reduce fire hazard/ weed growt | stimulate following bloom | suppress vegetative growth

ニュージーランド - 英語 - Medsafe (Medicines Safety Authority)

covidien nz ltd - ioversol 34% (provides 16% (160mg/ml) organically bound iodine) - solution for injection - 34 % - active: ioversol 34% (provides 16% (160mg/ml) organically bound iodine) excipient: sodium calcium edetate trometamol

ニュージーランド - 英語 - Medsafe (Medicines Safety Authority)

covidien nz ltd - ioversol 34% (provides 16% (160mg/ml) organically bound iodine) - solution for injection - 34 % - active: ioversol 34% (provides 16% (160mg/ml) organically bound iodine) excipient: sodium calcium edetate trometamol

アイルランド - 英語 - HPRA (Health Products Regulatory Authority)

chugai pharma uk ltd - lenograstim - pdr+solv for soln for inf/inj - 34 million iu/ml

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

neolife international pty ltd - glycine max, quantity: 225 mg (equivalent: linolenic acid, qty 16.65 mg); triticum aestivum, quantity: 150 mg (equivalent: gluten, qty 0 mg); triticum aestivum, quantity: 10 mg (equivalent: gluten, qty 0.004 mg); oryza sativa, quantity: 300 mg; oryza sativa, quantity: 10 mg; mixed (high-alpha type) tocopherols concentrate, quantity: 2 mg - capsule, soft - excipient ingredients: gelatin; yellow beeswax; titanium dioxide; chlorophyllin-copper complex; purified water; glycerol - antioxidant/reduce free radicals formed in the body ; maintain/support body metabolism/metabolic rate ; maintain/support energy production ; maintain/support eye health ; maintain/support healthy teeth ; anti-inflammatory/relieve inflammation ; maintain/support connective tissue health ; helps enhance/promote bone health ; maintain/support bone health ; helps enhance/promote healthy joint function ; maintain/support joint health ; maintain/support cardiovascular system health ; maintain/support healthy cardiovascular system function ; maintain/support heart health ; maintain/support immune system health ; maintain/support healthy immune system function ; maintain/support muscle health ; maintain/support muscle function ; helps maintain/support cellular uptake of (state vitamin/mineral/nutrient) ; helps prevent dietary (state vitamin/mineral/nutrient) deficiency ; maintain/support brain function ; maintain/support nervous system health ; maintain/support nervous system function

カナダ - 英語 - Health Canada

armitage carroll, division of langford inc. - piperazine - liquid - 34% - piperazine 34% - horses; poultry; swine (pigs)

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

baxter healthcare corporation - desflurane (unii: crs35bz94q) (desflurane - unii:crs35bz94q) - desflurane 240 ml in 240 ml - suprane is indicated as an inhalation agent for induction of anesthesia for inpatient and outpatient surgery in adults. suprane is contraindicated as an inhalation agent for the induction of anesthesia in pediatric patients because of a high incidence of moderate to severe upper airway adverse events. suprane is indicated as an inhalation agent for maintenance of anesthesia for inpatient and outpatient surgery in adults and in pediatric patients. after induction of anesthesia with agents other than suprane, and tracheal intubation, suprane is indicated for maintenance of anesthesia in infants and children. suprane is not approved for maintenance of anesthesia in non-intubated children due to an increased incidence of respiratory adverse reactions, including coughing, laryngospasm, and secretions [see warnings and precautions (5.3) and clinical studies (14.5) ]. the use of suprane is contraindicated in the following conditions: risk summary there are no adequate and well-controlled studies in pregnant women

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

par pharmaceutical - montelukast sodium (unii: u1o3j18sfl) (montelukast - unii:mhm278sd3e) - montelukast 10 mg - montelukast sodium is indicated for the prophylaxis and chronic treatment of asthma in adults and pediatric patients 2 years of age and older. montelukast sodium is indicated for prevention of exercise-induced bronchoconstriction (eib) in patients 6 years of age and older. montelukast sodium is indicated for the relief of symptoms of seasonal allergic rhinitis in patients 2 years of age and older and perennial allergic rhinitis in patients 2 years of age and older. hypersensitivity to any component of this product. risk summary available data from published prospective and retrospective cohort studies over decades with montelukast use in pregnant women have not established a drug-associated risk of major birth defects [see data ]. in animal reproduction studies, no adverse developmental effects were observed with oral administration of montelukast to pregnant rats and rabbits during organogenesis at doses approximately 100 and 110 times, respectively, the maximum recommended human daily oral dose (mrhdod) bas

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

amneal pharmaceuticals llc - itraconazole (unii: 304nug5gf4) (itraconazole - unii:304nug5gf4) - itraconazole 10 mg in 1 ml - itraconazole oral solution is indicated for the treatment of oropharyngeal and esophageal candidiasis. (see clinical pharmacology: special populations, warnings, and adverse reactions: post-marketing experience for more information). congestive heart failure: itraconazole oral solution should not be administered to patients with evidence of ventricular dysfunction such as congestive heart failure (chf) or a history of chf except for the treatment of life-threatening or other serious infections (see boxed warning, warnings, precautions: drug interactions-calcium channel blockers, adverse reactions: post-marketing experience, and clinical pharmacology: special populations ). co-administration of a number of cyp3a4 substrates are contraindicated with itraconazole. some examples of drugs for which plasma concentrations increase are: methadone, disopyramide, dofetilide, dronedarone, quinidine, isavuconazole, ergot alkaloids (such as dihydroergotamine, ergometrine (ergonovine), ergotamine, methylergometrine (methylergonovine)), irinotecan, lurasidone, oral midazolam, pimozide, triazolam, felodipine, nisoldipine, ivabradine, ranolazine, eplerenone, cisapride, naloxegol, lomitapide, lovastatin, simvastatin, avanafil, ticagrelor, finerenone, voclosporin. in addition, co-administration with colchicine, fesoterodine, and solifenacin is contraindicated in subjects with varying degrees of renal or hepatic impairment, and co-administration with eliglustat is contraindicated in subjects that are poor or intermediate metabolizers of cyp2d6 and in subjects taking strong or moderate cyp2d6 inhibitors (see precautions: drug interactions section for specific examples). this increase in drug concentrations caused by co-administration with itraconazole may increase or prolong both the pharmacologic effects and/or adverse reactions to these drugs. for example, increased plasma concentrations of some of these drugs can lead to qt prolongation and ventricular tachyarrhythmias including occurrences of torsade de pointes, a potentially fatal arrhythmia. some specific examples are listed in precautions: drug interactions. co-administration with venetoclax is contraindicated in patients with cll/sll during the dose initiation and ramp-up phase of venetoclax due to the potential for an increased risk of tumor lysis syndrome. itraconazole oral solution is contraindicated for patients who have shown hypersensitivity to itraconazole. there is limited information regarding cross-hypersensitivity between itraconazole and other azole antifungal agents. caution should be used when prescribing itraconazole to patients with hypersensitivity to other azoles.